A recent retrospective study from Singapore identified several factors associated with a higher risk of mortality following hip fracture, including male sex, older age, and a higher number of comorbidities.
The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
In the primary care setting, adding liraglutide to intensive behavioural therapy (IBT) conferred greater weight loss than IBT alone among individuals with obesity, results from the phase IIIB SCALE* IBT study showed.
Damage to small blood vessels of the eye appears to be a significant marker for an increased risk of stroke in patients with diabetes, suggesting that the microvascular pathology inherent to diabetic retinopathy may have greater cardiovascular implications, according to a study presented at the American Stroke Association’s (ASA) International Stroke Conference (ISC) 2020 in Los Angeles, US.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.